Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences

doi:10.1007/s13659-020-00253-1

Natural Products and Bioprospecting ›› 2020, Vol. 10 ›› Issue (5): 297-306.DOI: 10.1007/s13659-020-00253-1

• ORIGINAL ARTICLES • Previous Articles Next Articles

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences

Rohan R. Narkhede¹, Ashwini V. Pise¹, Rameshwar S. Cheke², Sachin D. Shinde³

1 Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research(NIPER), Raebareli, Lucknow 226002, India;
2 Department of Pharmaceutical Chemistry, Dr. Rajendra Gode College of Pharmacy, Makapur, Maharashtra 443101, India;
3 Department of Pharmacology, Shri. R. D. Bhakta College of Pharmacy, Jalna, Maharashtra 431203, India

Received:2020-05-16 Revised:2020-06-08 Online:2020-10-23 Published:2020-10-24
Contact: Rameshwar S. Cheke
Supported by:
The authors are grateful to Dr. V. N. Shrikhande, Principal, Dr. Rajendra Gode College of Pharmacy, Malkapur, (MS), India for providing necessary facilities.

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences

Rohan R. Narkhede¹, Ashwini V. Pise¹, Rameshwar S. Cheke², Sachin D. Shinde³

1 Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research(NIPER), Raebareli, Lucknow 226002, India;
2 Department of Pharmaceutical Chemistry, Dr. Rajendra Gode College of Pharmacy, Makapur, Maharashtra 443101, India;
3 Department of Pharmacology, Shri. R. D. Bhakta College of Pharmacy, Jalna, Maharashtra 431203, India

通讯作者: Rameshwar S. Cheke
基金资助:
The authors are grateful to Dr. V. N. Shrikhande, Principal, Dr. Rajendra Gode College of Pharmacy, Malkapur, (MS), India for providing necessary facilities.

Abstract

Abstract: SARS-CoV-2 (2019-nCoV) emerged in 2019 and proliferated rapidly across the globe. Scientists are attempting to investigate antivirals specific to COVID-19 treatment. The 2019-nCoV and SARS-CoV utilize the same receptor of the host which is COVID-19 of the main protease (Mpro).COVID-19 caused by SARS-CoV-2 is burdensome to overcome by presently acquired antiviral candidates. So the objective and purpose of this work was to investigate the plants with reported potential antiviral activity. With the aid of in silico techniques such as molecular docking and druggability studies, we have proposed several natural active compounds including glycyrrhizin, bicylogermecrene, tryptanthrine, β-sitosterol, indirubin, indican, indigo, hesperetin, crysophanic acid, rhein, berberine and β-caryophyllene which can be encountered as potential herbal candidate exhibiting anti-viral activity against SARS-CoV-2. Promising docking outcomes have been executed which evidenced the worthy of these selected herbal remedies for future drug development to combat coronavirus disease.

Key words: nCoV-2019, COVID-19 main protease, Herbal remedies, Docking study, Druggability

摘要： SARS-CoV-2 (2019-nCoV) emerged in 2019 and proliferated rapidly across the globe. Scientists are attempting to investigate antivirals specific to COVID-19 treatment. The 2019-nCoV and SARS-CoV utilize the same receptor of the host which is COVID-19 of the main protease (Mpro).COVID-19 caused by SARS-CoV-2 is burdensome to overcome by presently acquired antiviral candidates. So the objective and purpose of this work was to investigate the plants with reported potential antiviral activity. With the aid of in silico techniques such as molecular docking and druggability studies, we have proposed several natural active compounds including glycyrrhizin, bicylogermecrene, tryptanthrine, β-sitosterol, indirubin, indican, indigo, hesperetin, crysophanic acid, rhein, berberine and β-caryophyllene which can be encountered as potential herbal candidate exhibiting anti-viral activity against SARS-CoV-2. Promising docking outcomes have been executed which evidenced the worthy of these selected herbal remedies for future drug development to combat coronavirus disease.

关键词: nCoV-2019, COVID-19 main protease, Herbal remedies, Docking study, Druggability

Rohan R. Narkhede, Ashwini V. Pise, Rameshwar S. Cheke, Sachin D. Shinde. Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences[J]. Natural Products and Bioprospecting, 2020, 10(5): 297-306.

References

1. K. Leung, J. Wu, D. Liu, G. Leung, Lancet 395, p689-697 (2020)
2. A.J. Rodríguez-Morales, K. MacGregor, S. Kanagarajah, D. Patel, P. Schlagenhauf, Travel Med Infect. Dis. 33, 101578 (2020)
3. S. Khaerunnisa, H. Kurniawan, R. Awaluddin, S. Suhartati, Preprints (2020). https://doi.org/10.20944/preprints202003.0226.v1
4. Coronavirus Outbreak. (2020). https://www.worldometers.info/coronavirus/. Accessed 5 Apr 2020
5. H. Lu, Biosci. Trends 14, 69 (2020)
6. L. Zhang, D. Lin, X. Sun, U. Curth, C. Drosten, L. Sauerhering, S. Becker, K. Rox, R. Hilgenfeld, Science 368, 409 (2020)
7. K. Anand, H. Yang, M. Bartlam, Z. Rao, R. Hilgenfeld, R. Coronavirus main proteinase:target for antiviral drug therapy. In Coronaviruses with special emphasis on first insights concerning SARS, Birkhäuser Basel, 173-199 (2005)
8. H. Yang, M. Bartlam, Z. Rao, Curr. Pharm. Des. 12, 4573 (2006)
9. R.K. Ganjhu, P.P. Mudgal, H. Maity, D. Dowarha, S. Devadiga, S. Nag, G. Arunkumar, Virusdisease 26, 225 (2015)
10. P. Katona, J. Katona-Apte, Clin. Infect. Dis. 46, 1582 (2008)
11. G. Pinn, Aust. Fam. Physician 30, 681 (2001)
12. Medicinal plants and primary health care:part 2. Essent Drugs Monit, WHO (11):15-17 (1991)
13. G.B. Mahady, J. Nutr. 131, 1120S (1120S)
14. J. Zhang, I.J. Onakpoya, P. Posadzki, M. Eddouks, Evid. Based Complement. Altern. Med. 2015, 316706 (2015)
15. B. Vellingiri, K. Jayaramayya, M. Iyer, A. Narayanasamy, V. Govindasamy, B. Giridharan, S. Ganesan, A. Venugopal, D. Venkatesan, H. Ganesan, K. Rajagopalan, P.K.S.M. Rahman, S.G. Cho, N.S. Kumar, M.D. Subramaniam, Sci. Total Environ. 725, 138277 (2020)
16. R.R. Narkhede, R.S. Cheke, J.P. Ambhore, S.D. Shinde, Eurasian J Med. Oncol. 4, 185 (2020)
17. Q. Zhang, M. Ye, J. Chromatogr. A 1216, 1954 (2009)
18. X. Qiao, W. Song, S. Ji, Q. Wang, D. Guo, M. Ye, J. Chromatogr. A 1402, 36 (2015)
19. C. Fiore, M. Eisenhut, R. Krausse, E. Ragazzi, D. Pellati, D. Armanini, J. Bielenberg, Phytother. Res. 22, 141 (2008)
20. M.S. Ghannad, A. Mohammadi, S. Safiallahy, J. Faradmal, M. Azizi, Z. Ahmadvand, Jundishapur J. Microbiol. 7, e11616 (2014)
21. K. Hirabayashi, S. Iwata, H. Matsumoto, T. Mori, S. Shibata, M. Baba, M. Ito, S. Shigeta, H. Nakashima, N. Yamamoto, Chem. Pharm. Bull. (Tokyo). 39, 112 (1991)
22. U.A. Ashfaq, M.S. Masoud, Z. Nawaz, S. Riazuddin, J. Transl. Med. 9, 112 (2011)
23. M. Baba, S. Shigeta, Antivir. Res. 7, 99 (1987)
24. G. Hoever, L. Baltina, M. Michaelis, R. Kondratenko, L. Baltina, G.A. Tolstikov, H.W. Doerr, J. Cinatl, J. Med. Chem. 48, 1256 (2005)
25. D. Armanini, C. Fiore, M.J. Mattarello, J. Bielenberg, M. Palermo, Exp. Clin. Endocrinol. diabetes. 110, 257 (2002)
26. C. Fiore, M. Eisenhut, E. Ragazzi, G. Zanchin, D. Armanini, J. Ethnopharmacol. 99, 317 (2005)
27. J.G. Costa, E. Sousa, F. Rodrigues, S. de Lima, R. Braz-Filho, Rev. Bras. Farmacogn. 19, 710 (2009)
28. M.H. Assareh, K. Jaimand, M.B. Rezaee, J. Essent. Oil Res. 19, 8 (2007)
29. T.G. Santos, J. Laemmle, R.A. Rebelo, E.M. Dalmarco, A.B. Cruz, A.P. Schmit, R.C. Cruz, A.L. Zeni, J. Essent. Oil Res. 27, 125-130 (2015)
30. J. Montanha, P. Moellerke, S. Bordignon, E. Schenkel, P. Roehe, Acta Farm. Bonaer. 23, 183 (2004)
31. W. Lin, W. Huang, S. Ning, X. Wang, Q. Ye, D. Wei, PLoS ONE 13, e0199788 (2018)
32. Y.C. Tsai, C.L. Lee, H.R. Yen, Y.S. Chang, Y.P. Lin, S.H. Huang, C.W. Lin, Biomolecules 10, 366 (2020)
33. W. Gu, Y. Zhang, X.-J. Hao, F.-M. Yang, Q.-Y. Sun, S.L. MorrisNatschke, K.-H. Lee, Y.-H. Wang, C.-L. Long, J. Nat. Prod. 77, 2590 (2014)
34. S.-J. Chang, Y.-C. Chang, K.-Z. Lu, Y.-Y. Tsou, C.-W. Lin, Evid. Based Complement. Altern. Med. 2012, 925830 (2012)
35. Z. Hu, Y. Tu, Y. Xia, P. Cheng, W. Sun, Y. Shi, L. Guo, H. He, C. Xiong, S. Chen, X. Zhang, Evid. Based Complement. Altern. Med. 2015, 484670 (2015)
36. C.W. Lin, F.J. Tsai, C.H. Tsai, C.C. Lai, L. Wan, T.Y. Ho, C.C. Hsieh, P.D.L. Chao, Antivir. Res. 68, 36 (2005)
37. M.K. Parvez, M.T. Rehman, P. Alam, M.S. Al-Dosari, S.I. Alqasoumi, M.F. Alajmi, Saudi Pharm. J. 27, 389 (2019)
38. C.L. Lee, C.M. Wang, H.C. Hu, H.R. Yen, Y.C. Song, S.J. Yu, C.J. Chen, W.C. Li, Y.C. Wu, Phytochemistry 162, 39 (2019)
39. B.C. Liau, T.T. Jong, M.R. Lee, S.S. Chen, J. Pharm. Biomed. Anal. 43, 346 (2007)
40. A.M. Madureira, J.R. Ascenso, L. Valdeira, A. Duarte, J.P. Frade, G. Freitas, M.J.U. Ferreira, Nat. Prod. Res. 17, 375 (2003)
41. P. Zou, H.L. Koh, Rapid Commun. Mass Spectrom. 21, 1239 (2007)
42. G.W. Qin, R.S. Xu, Med. Res. Rev. 18, 375 (1998)
43. Y.S. Han, G.G. Chang, C.G. Juo, H.J. Lee, S.H. Yeh, J.T.A. Hsu, X. Chen, Biochemistry 44, 10349 (2005)
44. L. Chen, T. Lin, H. Zhang, Y. Su, Intervirology 48, 207 (2005)
45. Y.M. Li, X.M. Li, G.M. Li, W.C. Du, J. Zhang, W.X. Li, J. Xu, M. Hu, Z. Zhu, J. Agric. Food Chem. 56, 5550 (2008)
46. X. Yu, S. Sun, Y. Guo, Y. Liu, D. Yang, G. Li, S. Lü, J. Ethnopharmacol. 220, 265 (2018)
47. X. Bai, P. Yang, Q. Zhou, B. Cai, M. Buist-Homan, H. Cheng, J. Jiang, D. Shen, L. Li, X. Luo, K.N. Faber, H. Moshage, G. Shi, Br. J. Pharmacol. 174, 41 (2017)
48. W. Dong, X. Wei, F. Zhang, J. Hao, F. Huang, C. Zhang, W. Liang, Sci. Rep. 4, 7237 (2014)
49. N. Chinchilla, C. Carrera, A.G. Durán, M. Macías, A. Torres, F.A. Macías, Phytochem. Rev. 12, 581 (2013)
50. C. Shen, Z. Zhang, T. Xie, J. Ji, J. Xu, L. Lin, J. Yan, A. Kang, Q. Dai, Y. Dong, J. Shan, S. Wang, X. Zhao, Front. Pharmacol. 10, 1600 (2020)
51. Q.W. Wang, Y. Su, J.T. Sheng, L.M. Gu, Y. Zhao, X.X. Chen, C. Chen, W.Z. Li, K.S. Li, J.P. Dai, PLoS ONE 13, e0191793 (2018)
52. H. Wang, K. Li, L. Ma, S. Wu, J. Hu, H. Yan, J. Jiang, Y. Li, Virol. J. 14, 2 (2017)
53. A. Astani, J. Reichling, P. Schnitzler, Evid. Based Complement. Altern. Med. 2011, 253643 (2011)
54. K. Hayashi, K. Minoda, Y. Nagaoka, T. Hayashi, S. Uesato, Bioorg. Med. Chem. Lett. 17, 1562 (2007)
55. Y.Q. Yan, Y.J. Fu, S. Wu, H.Q. Qin, X. Zhen, B.M. Song, Y.S. Weng, P.C. Wang, X.Y. Chen, Z.Y. Jiang, Phyther. Res. 32, 2560 (2018)
56. H.B. Shin, M.S. Choi, C.M. Yi, J. Lee, N.J. Kim, K.S. Inn, Int. Immunopharmacol. 27, 65 (2015)
57. F.S. Varghese, B. Thaa, S.N. Amrun, D. Simarmata, K. Rausalu, T.A. Nyman, A. Merits, G.M. McInerney, L.F.P. Ng, T. Ahola, J. Virol. 90, 9743 (2016)
58. M. Dkhil, S. Al-Quraishy, J. Pure Appl. Microbiol. 8, 155 (2014)
59. Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Zhao, B. Zhang, X. Li, L. Zhang, C. Peng, Y. Duan, Structure of Mpro from COVID-19 virus and discovery of its inhibitors. bioRxiv. Preprint. 2020.
60. K. Cousins, J. Am. Chem. Soc. 133, 8388 (2011)
61. A. Pedretti, L. Villa, G. Vistoli, J. Comput. Aided. Mol. Des. 18, 167 (2004)
62. O. Trott, A.J. Olson, J. Comput. Chem. 31, 455 (2010)
63. G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J. Olson, J. Comput. Chem. 30, 2785 (2009)
64. D. Seeliger, B.L. de Groot, J. Comput. Aided. Mol. Des. 24, 417 (2010)
65. L.Z. Benet, C.M. Hosey, O. Ursu, T.I. Oprea, Adv. Drug Deliv. Rev. 101, 89 (2016)
66. C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Adv. Drug Deliv. Rev. 46, 3 (2001)
67. A. Daina, O. Michielin, V. Zoete, Sci. Rep. 7, 42717 (2017)

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments